English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The purpose of this study was to assess the response rate, toxicity, progression-freesurvival (PFS) and overall survival (OS) in a series of advanced stage ovariancarcinoma patients treated with a first-line weekly docetaxel and three weeklycarboplatin regimens. All eligible patients were treated with intravenous docetaxel(30 mg/m2) on Days 1, 8 and 15, and carboplatin (area under the curve, 5) on Day1; Q21 days for at least 6 cycles. Neurological tests, questionnaires, and theEORTC QLQ-C30 and OV28 were used for quality-of-life assessments. One hundredand six patients received at least one cycle of primary chemotherapy (median 6.0;range, 1-9) and they were evaluable for toxicity assessment. Eighty-five patientshad evaluable disease and received at least 3 courses of chemotherapy and wereevaluable for clinical response rate. The overall response rate was 78.8% (95%CI 70.1-87.5%) and the biochemical response was 92.8% (95% CI 87.2-98.4%). Themedian PFS was 12.0 months and the median OS was 35.3 months. Thirty-six patients(34.0%) experienced grades 3 and 4 neutropenia, which resulted in the removalof 3 patients. Six patients (5.7%) experienced grades 3 or 4 thrombocytopenia.No patients experienced grade 3-4 sensory neuropathy. Epiphora, nail changes andfatigue were frequently recorded non-hematological side effects. The tolerablehematological toxicity (no need for colony-stimulating factors) and the low rateof severe neurotoxicity (only grade 1-2) and response rates in line with the standard3-week paclitaxel-carboplatin regimen for advanced primary ovarian carcinoma aftersuboptimal cytoreductive surgery make this regimen an interesting alternativein selected patients.

international journal of oncology

A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: Neurological toxicity and quality-of-life evaluation